银屑病关节炎患者中TNF抑制剂治疗的长期持续性:来自英国风湿病学会生物制剂登记的数据
基于英国风湿病学会生物制剂登记(BSRBR)2002—2006年注册的银屑病关节炎(PsA)患者,描述首次TNF抑制剂(TNFi)治疗的5年持续性并分析相关因素,同时评估后续TNFi治疗的持续性。5年时46.7%的患者仍在初始TNFi治疗;第一、二、三次TNFi的5年持续性估计分别为53%(95%CI 49%~57%)、60%(95%CI 43%~57%)和48%(95%CI 36%~59%)。
要点
- 5年时46.7%的PsA患者仍在初始TNFi治疗。
- 男性、使用依那西普或阿达木单抗而非英夫利西单抗、无基线合并症与更好的5年持续性相关。
- 第一、二、三次TNFi的5年持续性估计分别为53%、60%和48%。
核心结论
- 在该PsA人群中,首次及后续TNFi治疗均观察到良好的长期持续性。
- 持续性与相关临床因素之间的关系不强,显示预测PsA中TNFi治疗结局存在困难。
研究设计与样本
- 纳入英国风湿病学会生物制剂登记(BSRBR)2002—2006年注册、由风湿病学家诊断为PsA并接受首次TNFi治疗的患者。
- 描述不同时间点的治疗情况,采用逻辑回归识别与5年治疗持续性相关的因素。
- 采用Kaplan-Meier分析评估与首次TNFi及后续TNFi治疗持续性相关的因素。
主要发现
- 5年时46.7%的患者仍在初始TNFi治疗。
- 更好的5年持续性与男性、使用依那西普或阿达木单抗而非英夫利西单抗、以及无基线合并症相关。
- 第一、二、三次TNFi的5年持续性估计(95%CI)分别为53%(49%~57%)、60%(43%~57%)和48%(36%~59%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term effectiveness of tumour necrosis factor alpha inhibitors (TNFi) has mainly been explored in patients with rheumatoid arthritis (RA) and the data available on patients with psoriatic arthritis (PsA) includes limited follow-up. OBJECTIVE: Investigate long-term effectiveness of first TNFi in a PsA population by describing treatment persistence, identify factors associated with 5-year persistence and further investigate comparative long-term effectiveness of subsequent TNFi treatments through persistence to treatment. METHODS: Patients with a rheumatologist diagnosis of PsA receiving their first TNFi registered in the British Society for Rheumatology Biologics Register (BSRBR) (2002-2006) were included. Treatment at different time points was described and factors associated with 5-year treatment persistence were identified by logistic regression. Kaplan-Meier analysis was used to assess factors associated with persistence to first TNFi and subsequent TNFi treatments. RESULTS: At 5 years, 46.7% of patients were still on their initial TNFi treatment. Better 5 -year persistence was associated with male gender, use of etanercept or adalimumab rather than infliximab and absence of baseline comorbidity. Five-year persistence estimates (95% CI) of first, second and third TNFi were 53% (49% to 57%), 60% (43% to 57%) and 48% (36% to 59%), respectively. CONCLUSION: We found good long-term persistence of TNFi in this PsA population both for the first and subsequent TNFi treatments. The relationship between persistence and relevant clinical factors was not strong and demonstrates the difficulties in predicting outcome of TNFi treatment in PsA.
引用
- Fagerli KM, Kearsley-Fleet L, Watson KD, et al. Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. RMD Open. 2018. PMID: 29479475. doi:10.1136/rmdopen-2017-000596
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。